Intercept price target raised to $525 from $360 at Oppenheimer Oppenheimer increased its price target on Intercept after updating its valuation estimate of the company's OCA drug after positive data for the drug was reported. The firm thinks the stock could rise further as investors focus on potentially positive upcoming fibrosis data. Oppenheimer keeps an Outperform rating on the shares.
Intercept initiated with a Buy, $465 target at UBS UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.